6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson's disease

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 4, 2015, Pages 393-399

  Theodore, Shaji ^a   Maragos, William ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glia; immunoglobulins; lymphocytes; neuroimmunology; neurotoxin

Indexed keywords

DOPAMINE; IMMUNOGLOBULIN G; OXIDOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TYROSINE 3 MONOOXYGENASE; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CD3 ANTIGEN; CD45 ANTIGEN; CYBB PROTEIN, MOUSE; MEMBRANE PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PARKINSONISM; PATHOLOGY; T LYMPHOCYTE;

MUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD3; ANTIGENS, CD45; B-LYMPHOCYTES; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; NADPH OXIDASE; NERVE DEGENERATION; OXIDOPAMINE; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; T-LYMPHOCYTES;

EID: 84938883340     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1070172     Document Type: Article

References (21)

1. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004;1:139-154.
2. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008;23:474-483.
3. Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008;3:e1376.
4. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Investig 2009;119:182-192.
5. Cao S, Theodore S, Standaert DG. Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegeneration 2010;5:42. doi: 10.1186/1750-1326-5-42.
6. Orr CF, Rowe DB, Mizuno Y, et al. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005;128:2665-2674.
7. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008;67:1149-1158.
8. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
9. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-494.
10. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 2007;11:151-167.
11. Choi SH, Aid S, Kim HW, et al. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 2012;120:292-301.
12. Rodriguez-Pallares J, Parga JA, Munoz A, et al. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 2007;103:145-156.
13. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a009381.
14. Cao JJ, Li KS, Shen YQ. Activated immune cells in Parkinson's disease. J Neuroimmune Pharmacol 2011;6:323-329.
15. He Y, Le WD, Appel SH. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002;176:322-327.
16. Chen S, Le WD, Xie WJ, et al. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998;55:1075-1080.
17. St Martin JL, Klucken J, Outeiro TF, et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007;100:1449-1457.
18. Choi DH, Cristovao AC, Guhathakurta S, et al. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 2012;16:1033-1045.
19. Babior BM. NADPH oxidase. Curr Opin Immunol 2004;16:42-47.
20. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:6145-6150.
21. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-788.